[et_pb_section fb_built=”1″ admin_label=”OptiRiMox Section” _builder_version=”4.21.0″ custom_margin=”150px||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” max_width=”none” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”OptiRiMox” _builder_version=”4.27.4″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”||-3px|||” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”2_3,1_3″ _builder_version=”4.27.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” max_width=”none” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n
This study is part of the\u00a0 capacity development programme within SimpliciTB<\/a>, and is sponsored and led by KIDH, Tanzania, managed by St Andrews, supported by UCL<\/a> and Radboud UMC<\/a>.\u00a0 It is a pragmatic trial with optimized dose of rifampicin and moxifloxacin for the treatment of drug susceptible pulmonary tuberculosis (DS-TB) in primary care facilities in Blantyre, Malawi and across three other African countries namely Gabon, Mozambique, and Tanzania.<\/p>\n The trial is led by Kibong’oto Infectious Disease Hospital KIDH in Tanzania who are working with the University of St Andrews<\/a>, Kamuzu University of Health Sciences KUHeS<\/a>, Malawi, Centre de Recherches M\u00e9dicales de Lambar\u00e9n\u00e9 CERMEL<\/a>, Gabon and Instituto Nacionale De Sa\u00fade INS<\/a>, Mozambique.<\/p>\n OptiRiMoxTB will establish whether a 4-month therapy based on rifampicin (35mg\/kg) +\/- Moxifloxacin (400 mg) is non-inferior to conventional 6-month DS-TB therapy.<\/p>\n The OptiRiMox study emerges from longstanding UStAn collaborations in Africa and our programme of tuberculosis drug development.<\/p>\n OptiRiMoxTB is funded by European & Developing Countries Clinical trials Partnership EDCTP<\/a> and is part of a larger International clinical trial, SimpliciTB<\/a> that provided funding for capacity development; objectives to extend and strengthen network of African clinical trial sites.\u00a0 The University of St Andrews is coordinating and providing mentorship to the 4 recruiting sites in four countries, KIDH (Tanzania), CERMEL<\/a> (Gabon), KUHeS<\/a> (Malawi) and INS<\/a> (Mozambique), along with Internationally experienced partners \u00a0TBAlliance<\/a>, Radboud<\/a>, UCL<\/a>, TASK<\/a>, NIMRMbeya<\/a>.<\/p>\n The OptiRiMoxTB study will use the UStAn innovation: the TB-Molecular Bacterial Load Assay tool<\/a> in the trial to measure treatment response.\u00a0 This assay measures the number of TB bacteria in a patient sample in a matter of hours and monitors the effectiveness of medicine in killing the bacteria as treatment progresses and will be the used in the Trial.<\/p>\n Infrastructure support and a newly developed framework to measure and evaluate community engagement<\/a> will also be used in the trial.<\/p>\n Tuberculosis causes about a million deaths every year. To change this and save lives, new tools, especially better treatments, are required.\u00a0 Tuberculosis is preventable and treatable!<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-content\/uploads\/sites\/50\/2026\/03\/OptiRiMox-Chart-for-Website.png” title_text=”OptiRiMox-Chart-for-Website” admin_label=”Image” _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.27.5″ _module_preset=”default” max_width=”none” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_divider _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ make_equal=”on” _builder_version=”4.27.5″ _module_preset=”default” max_width=”none” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_column type=”1_4″ _builder_version=”4.27.5″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_image src=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-content\/uploads\/sites\/50\/2026\/03\/TZM0405_Stellah-Mpagama.png” title_text=”TZM0405_Stellah-Mpagama” _builder_version=”4.27.5″ _module_preset=”default” max_width=”160px” custom_margin=”||||false|false” hover_enabled=”0″ border_radii=”on|150px|150px|150px|150px” global_colors_info=”{}” align=”center” sticky_enabled=”0″][\/et_pb_image][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”-10px|10px|10px|10px|false|false” custom_padding=”||||false|false” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n Prof.Stella Mpagama, Principal Investigator<\/p>\n Senior EDCTP Fellow and honorary member of staff at the University of St Andrews<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-content\/uploads\/sites\/50\/2026\/03\/Alphonce-2-scaled.png” title_text=”Alphonce-2″ _builder_version=”4.27.5″ _module_preset=”default” max_width=”160px” custom_margin=”||||false|false” border_radii=”on|150px|150px|150px|150px” global_colors_info=”{}” sticky_enabled=”0″ align=”center”][\/et_pb_image][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n Dr Alphonce Liyoyo,\u00a0Research Manager and Head of Clinical Trial Operations<\/p>\n Kibong’oto Infectious Disease Hospital<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" OptiRiMoxTB (New)This study is part of the\u00a0 capacity development programme within SimpliciTB, and is sponsored and led by KIDH, Tanzania, managed by St Andrews, supported by UCL and Radboud UMC.\u00a0 It is a pragmatic trial with optimized dose of rifampicin and moxifloxacin for the treatment of drug susceptible pulmonary tuberculosis (DS-TB) in primary care facilities […]<\/p>\n","protected":false},"author":159,"featured_media":0,"parent":3571,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":" This study is part of the\u00a0 capacity development programme within SimpliciTB<\/a>, and is sponsored and led by KIDH<\/a>, Tanzania, managed by St Andrews, supported by UCL<\/a> and Radboud UMC<\/a>.\u00a0 It is a pragmatic trial with optimized dose of rifampicin and moxifloxacin for the treatment of drug susceptible pulmonary tuberculosis (DS-TB) in primary care facilities in Blantyre, Malawi and across three other African countries namely Gabon, Mozambique, and Tanzania.<\/p>","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-5927","page","type-page","status-publish","hentry"],"publishpress_future_action":{"enabled":false,"date":"2026-04-15 11:18:24","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/5927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/users\/159"}],"replies":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/comments?post=5927"}],"version-history":[{"count":3,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/5927\/revisions"}],"predecessor-version":[{"id":7026,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/5927\/revisions\/7026"}],"up":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/3571"}],"wp:attachment":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/media?parent=5927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Team<\/h1>\n